Zydus Lifesciences Limited (BOM: 532321)

Market Cap	1.00T
Revenue (ttm)	214.84B
Net Income (ttm)	43.03B
Shares Out	n/a
EPS (ttm)	42.65
PE Ratio	23.28
Forward PE	n/a
Dividend	3.00 (0.30%)
Ex-Dividend Date	Jul 26, 2024

Volume	6,258
Average Volume	54,877
Open	1,013.35
Previous Close	994.15
Day's Range	982.00 - 1,013.35
52-Week Range	706.00 - 1,323.90
Beta	n/a
RSI	53.15
Earnings Date	Feb 4, 2025

About Zydus Lifesciences

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management...

• Industry: Pharmaceutical Preparations
• Founded: 1952
• Employees: 26,921
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532321

Financial Performance

In 2023, Zydus Lifesciences's revenue was 195.47 billion, an increase of 13.40% compared to the previous year's 172.37 billion. Earnings were 38.60 billion, an increase of 96.88%.